Economic analysis of final effluent limitations guidelines and standards for the pharmaceutical manufacturing industry

Technical Report · Wed Jul 01 04:00:00 EDT 1998

OSTI ID:293168

This economic analysis (EA) examines compliance costs and economic impacts resulting from the US Environmental Protection Agency`s (EPA`s) Final Effluent Limitations Guidelines and Standards for the Pharmaceutical Manufacturing Industry Point Source Category. It also investigates the costs and impacts associated with an air rule requiring Maximum Achievable Control Technology (MACT) to control air emissions, both separately and together with the Final Pharmaceutical Industry Effluent Guidelines. The EA estimates the economic effects of compliance with both final rules in terms of total aggregate annualized costs of compliance, facility closures, impacts on firms (likelihood of bankruptcy and effects on profit margins), and impacts on new sources. The EA also investigates secondary impacts on employment and communities, foreign trade, specific demographic groups, and environmental justice. This report includes a Final Regulatory Flexibility Analysis (FRFA) detailing the impacts on small businesses within the pharmaceutical industry to meet the requirements of the Regulatory Flexibility Act (RFA), as amended by the Small Business Regulatory Enforcement Fairness Act (SBREFA). Finally, the EA presents a cost-benefit analysis to meet the requirements of Executive Order 12866 and the Unfunded Mandates Reform Act.

• Research Organization: Environmental Protection Agency, Office of Water, Washington, DC (United States)
• OSTI ID: 293168
• Report Number(s): PB--99-112070/XAB; EPA--821/B-98/009
• Country of Publication: United States
• Language: English

Related Subjects

29 ENERGY PLANNING, POLICY, AND ECONOMY
AIR POLLUTION CONTROL
COST BENEFIT ANALYSIS
DRUGS
ECONOMIC IMPACT
MANUFACTURING
POLLUTION REGULATIONS
US EPA
WASTE WATER
WATER POLLUTION CONTROL
WATER TREATMENT